A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment

作者：Alberti Diego; Protti Nicoletta; Toppino Antonio; Deagostino Annamaria; Lanzardo Stefania; Bortolussi Silva; Altieri Saverio; Voena Claudia; Chiarle Roberto; Crich Simonetta Geninatti^*; Aime Silvio

来源：Nanomedicine: Nanotechnology, Biology and Medicine , 2015, 11(3): 741-750.

DOI：10.1016/j.nano.2014.12.004

• Low density lipoproteins (LDL)
• Boron Neutron Capture Therapy (BNCT)
• MRI
• Theranostic agents
• Carboranes

This study aims at developing an innovative theranostic approach for lung tumor and metastases treatment, based on Boron Neutron Capture Therapy (BNCT). It relies on to the use of low density lipoproteins (LDL) as carriers able to maximize the selective uptake of boron atoms in tumor cells and, at the same time, to quantify the in vivo boron distribution by magnetic resonance imaging (MRI). Tumor cells uptake was initially assessed by ICP-MS and MRI on four types of tumor (TUBO, B16-F10, MCF-7, A549) and one healthy (N-MUG) cell lines. Lung metastases were generated by intravenous injection of a Her2+ breast cancer cell line (i. e. TUBO) in BALB/ c mice and transgenic EML4-ALK mice were used as primary tumor model. After neutron irradiation, tumor growth was followed for 30-40 days by MRI. Tumor masses of boron treated mice increased markedly slowly than the control group.
From the Clinical Editor: In this article, the authors described an improvement to existing boron neutron capture therapy. The dual MRI/ BNCT agent, carried by LDLs, was able to maximize the selective uptake of boron in tumor cells, and, at the same time, quantify boron distribution in tumor and in other tissues using MRI. Subsequent in vitro and in vivo experiments showed tumor cell killing after neutron irradiation.

• 出版日期2015-4